Similar articles

• Altered platelet 3H-imipramine binding in schizo-affective and depressive disorders.

  Suranyi-Cadotte BE, Wood PL, Schwartz G, Nair NP. Suranyi-Cadotte BE, et al. Biol Psychiatry. 1983 Aug;18(8):923-7. Biol Psychiatry. 1983. PMID: 6311293 No abstract available.
• Diurnal and circannual variation in platelet 3H-imipramine binding: comparative data on normal and affectively ill subjects.

  Baron M, Barkai A, Kowalik S, Fieve RR, Quitkin F, Gruen R. Baron M, et al. Neuropsychobiology. 1988;19(1):9-11. doi: 10.1159/000118425. Neuropsychobiology. 1988. PMID: 2847077
• Effect of protein concentration on kinetic constants (Kd and Bmax) of 3H-imipramine binding in blood platelets.

  Arora RC, Wunnicke V, Meltzer HY. Arora RC, et al. Biol Psychiatry. 1985 Jan;20(1):116-9. doi: 10.1016/0006-3223(85)90146-5. Biol Psychiatry. 1985. PMID: 2981127
• WHO pilot study on the validity of imipramine platelet receptor binding sites as a biological marker of endogenous depression. A preliminary report on the initial evaluation phase of a World Health Organization Collaborative Study.

  Bech P, Eplov L, Gastpar M, Gentsch C, Mendlewicz J, Plenge P, Rielaert C, Mellerup ET. Bech P, et al. Pharmacopsychiatry. 1988 May;21(3):147-50. doi: 10.1055/s-2007-1014667. Pharmacopsychiatry. 1988. PMID: 2841696 Review. No abstract available.
• Imipramine binding in depression and other psychiatric conditions.

  Mellerup ET, Plenge P. Mellerup ET, et al. Acta Psychiatr Scand Suppl. 1988;345:61-8. doi: 10.1111/j.1600-0447.1988.tb08569.x. Acta Psychiatr Scand Suppl. 1988. PMID: 2852451 Review.